Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
7 evidence topics · 6 sources
Genomic alterations of HPV-negative tumors
“HPV-negative tumours are enriched for CDKN2A and TP53 alterations, frequent focal deletions in other TSGs (such as NSD1, FAT1, NOTCH1 and SMAD4) and frequent focal amplification of the genes encoding the receptor tyrosine kinases EGFR, HER2 (also known as ERBB2) and FGFR1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Field cancerization in HPV-negative disease
“Rather, HPV-negative HNSCC arises from the grossly normal upper aerodigestive mucosa subject to ‘epithelial field cancerization’, where chronic exposure to carcinogens has resulted in molecular changes preconditioning towards malignant progression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EGFR, TGF-beta, and immune exclusion in HPV-negative disease
TGF-beta in immune evasion and resistance to EGFR antibodies
“Factors in the HNSCC TME, including IL-10 and TGFβ, also promote macrophage polarization to the immunosuppressive M2 phenotype” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, it has been shown that elevated levels of TGF-β in the TME are associated with immune evasion and resistance to cetuximab therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TGF-β can also induce EMT through its transactivation of EGFR, synergistically leading to increased tumor invasion and therapy resistance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote